Detects the MLL partial tandem duplication (PTD) between exons 2 and 8 in the MLL gene.

disease state indication(s)
Acute myeloid leukemia (AML)

clinical use
MLL partial tandem duplication (PTD) is found in approximately 5-11% of cytogenetically normal acute myeloid leukemia (AML) and up to 90% of AML with trisomy 11. In patients with AML, MLL-PTD is an adverse prognostic indicator for overall survival [1-2].
References:
1. Dohner H, et al. Acute myeloid leukemia. N Engl J Med 2015;373:1136-52.
2. Patel J, et al. Prognostic relevance of integrated genetic in acute myeloid leukemia. N Engl J Med 2012;366:1079-89.

methodology/product platform
Polymerase chain reaction (PCR)

specimen type and requirements
Peripheral blood: 2-3 mL in EDTA (purple-top) tube.
Bone marrow: 2-3 mL in EDTA (purple-top) tube.
Note: Use refrigerated cold pack for transport. Make sure cold pack is not in direct contact with specimen.
DO NOT FREEZE.

turnaround time
Global (TC & PC): 8 days

cpt code(s)
81479 (x1)

medicare moldx cpt code
Not applicable

regulatory classification
Laboratory developed test (LDT)

ordering option
Global (TC & PC)